Global Pharmaceutical Partnering Terms and Agreements 2010 to 2016 report provides a detailed understanding and analysis of how and why companies enter Pharmaceutical partnering deals.
This report provides details of the latest Pharmaceutical agreements announced in the life sciences since 2010.
The report takes the reader through a comprehensive review Pharmaceutical deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Pharmaceutical partnering deals.
The report presents financial deal term values for Pharmaceutical deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.
The middle section of the report explores the leading dealmakers in the Pharmaceutical partnering field; both the leading deal values and most active Pharmaceutical dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.
One of the key highlights of the report is that over 8,000 online deal records of actual Pharmaceutical deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.
Pharmaceutical Partnering Terms and Agreements includes:
Trends in Pharmaceutical dealmaking in the biopharma industry since 2010
Analysis of Pharmaceutical deal structure
Access to headline, upfront, milestone and royalty data
Case studies of real-life Pharmaceutical deals
Access to Pharmaceutical contract documents
Leading Pharmaceutical deals by value since 2010
Most active Pharmaceutical dealmakers since 2010
In Global Pharmaceutical Partnering 2010-2016: Deal trends, players, financials and forecasts, the available deals are listed by: